Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2011 Nov 1.

Published in final edited form as: Stem Cell Res. 2010 Aug 6;5(3):212–225. doi: 10.1016/j.scr.2010.07.003

(A); In comparison to CD45+CD19+ MCL cells, CD45+CD19− MCL-ICs displayed increased rhodamine efflux activities (Rho123 low populations), indicative of ABC transporter activities. Relative percentages of Rho123 low cells in patient samples are indicated in the boxed areas.

(B); MCL-ICs are quiescent based on Hoechst (Hst), and PyroninY (PY) expression. Patient tumor cells (Pt1) were analyzed for CD45 and CD19 expression as well as Hst and PY stainings. CD45+CD19− fractions are enriched for G0 phase cells (79%) and CD45+CD19+ fractions are enriched for G1/S/G2+M phase cells (58%). CD3 and CD34 positive cells were depleted prior to Rho123 staining and Hst/Py staining.

(A); In comparison to CD45+CD19+ MCL cells, CD45+CD19− MCL-ICs displayed increased rhodamine efflux activities (Rho123 low populations), indicative of ABC transporter activities. Relative percentages of Rho123 low cells in patient samples are indicated in the boxed areas.

(B); MCL-ICs are quiescent based on Hoechst (Hst), and PyroninY (PY) expression. Patient tumor cells (Pt1) were analyzed for CD45 and CD19 expression as well as Hst and PY stainings. CD45+CD19− fractions are enriched for G0 phase cells (79%) and CD45+CD19+ fractions are enriched for G1/S/G2+M phase cells (58%). CD3 and CD34 positive cells were depleted prior to Rho123 staining and Hst/Py staining.